We assessed the effects of the angiotensin II (Ang II) type 1 receptor (AT 1 -receptor) blocker, candesartan, (CN, 1 mg/kg i.v. over 30 minutes pre-ischaemia) alone or after intracoronary administration of Ang II type 2 receptor (AT 2 -receptor) blocker (PD 123319), protein kinase C (PKC) inhibitor (chelerythrine), endothelial nitric oxide (NO) synthase inhibitor (N G -monomethyl-L-arginine or L-NMMA), and bradykinin (BK) -B 2 receptor inhibitor (HOE140) on in vivo left ventricular (LV) function and remodelling (echocardiograms/ Doppler) and haemodynamics in 30 dogs with reperfused anterior infarction (90 minutes ischaemia, 120 minutes reperfusion), and ex vivo infarct size, AT 1 -receptor/AT 2 -receptor proteins and PKC ε (immunoblots), and cyclic guanosine 3', 5' monophosphate (cGMP, immunoassay). Compared with controls, CN inhibited the Ang II pressor response, reduced LV preload, improved LV systolic and diastolic function, limited LV remodelling, decreased infarct size, and increased AT 2 -receptor and PKC ε proteins in the infarct zone (IZ), and these responses were abrogated by PD 123319, chelerythrine, L-NMMA and HOE140. In addition, the increase in LV cGMP with CN was attenuated by PD 123319, L-NMMA and HOE140. The overall results suggest that AT 2 -receptor activation and signalling via BK, PKCε and cGMP contribute to cardioprotection associated with AT 1 -receptor blockade during ischaemia-reperfusion injury.
Introduction
Angiotensin II type 1 receptor (AT 1 -receptor) blockade has been shown to protect myocardium during ischaemia-reperfusion (IR), 1-6 acute myocardial infarction, 7 and chronic heart failure. 8 Recent studies have suggested that Ang II type 2 receptor (AT 2 -receptor) activation contributes to the cardioprotection associated with AT 1 -receptor blockade. [4] [5] [6] 8, 9 It has been proposed that the AT 2 -receptor activation may lead to increased bradykinin (BK), release of nitric oxide (NO) and increased cyclic guanosine 3', 5' monophosphate (cGMP), [4] [5] [6] 8, 9 and activation of protein kinase C ε (PKC ε ) expression. 5, 6 The aim of this study was to verify whether the cardioprotection associated with AT 1 -receptor blockade during IR, as well as the increases in AT 2receptor and PKC ε proteins and cGMP, are attenuated by AT 2 -receptor blockade or inhibition of PKC, NO synthase, and BK.
Methods

Experimental model
All experiments conformed with guidelines of the institutional animal care committee and the 'Position of the American Heart Association Research Animal Use' adopted by the AHA in November 1984. As described previously, 5, 6, 10, 11 healthy mongrel dogs (weight, 12 to 22 kg) were anaesthetised (sodium pentobarbital, 30 mg/kg i.v.). Neck incisions and left thoracotomies were performed. In each case, heparinised catheters were inserted in the external jugular vein, internal carotid artery and left atrium for haemodynamic monitoring and a silk snare was placed around the mid left anterior descending (LAD) coronary artery at the mid LV level, just below the second diagonal branch, for occlusion and reperfusion.
Experimental protocol
The animals were randomised to seven groups. Previous studies 5, 10 indicated that pretreatment with the AT 1 -receptor antagonist, candesartan, administered over 30 minutes intravenously before ischaemia, resulted in cardioprotection, associated with regional increases in AT 2 -receptor and PKC ε proteins, as well as cGMP, in the infarct zone. To block these regional responses, we used intracoronary infusions of the antagonists. This route was also necessary because of the prohibitive cost of intravenous infusions of these compounds into large animals. Five treatment groups (n=6 each) therefore had intracoronary infusions of saline or AT 2 -receptor blocker (PD 123319, 3 µg/kg/min), 4 PKC inhibitor (chelerythrine, 17 µg/kg/min), 11 endothelial NOS inhibitor (N Gmonomethyl-L-arginine [L-NMMA], 75 µg/kg/min), 12 or BK B 2 receptor antagonist inhibitor (HOE140, 10 ng/kg/min) 4 over 30 minutes into the LAD bed (distal to the site of the silk snare for IR), followed by 30 minutes intravenous infusions of candesartan (CN; CV-11974,Astra Pharma Inc., Mississauga, Ontario; 1 mg/kg in 40 mL saline) and IR. Effective blockade has been previously demonstrated with these doses of AT 2 -receptor, 4 PKC, 11 NOS, 12 and BK blockers. 4 Control animals had saline infusions and IR (n=6), whilst sham animals (n=6) had no IR. AT 1 -receptor blockade was confirmed by inhibition of the pressor response to exogenous Ang II (0.25 µg/kg i.v.) given before (baseline) and after the infusions. Ischaemia was produced by tight-ening the LAD snare for 90 minutes. Reperfusion was performed by releasing the snare for 120 minutes. As described previously, 5, 6, 10, 13, 14 electrocardiograms (ECGs) and haemodynamics (P23Db transducer for left atrial and arterial pressures; data acquisition system, Dataq Instruments Inc. Akron, OH) and two-dimensional echocardiograms and transmitral Doppler (Hewlett-Packard, Sono 1000; 3.5 or 5 MHz transducer) were recorded at four intervals: (1) baseline before infusions; (2) at the end of the infusion and just before LAD occlusion;
(3) after 90 minutes of LAD occlusion and just before reperfusion; and (4) at 120 minutes after reperfusion. Echocardiograms were recorded in parasternal long-and short-axis planes (at mitral, chordal, mid-papillary, low papillary and apical levels) and apical four-and two-chamber planes, and transmitral Doppler in the apical four-chamber plane. These recordings were stored on optical disc and videotape for off-line analysis. Doppler records of early (E) and late (A) filling velocities were analysed for the peak E/A ratio (filling fraction) and the deceleration time (DT). 5, 6, 15 
Measurement of risk region and infarct size
After the final recordings, the LAD coronary artery was re-occluded. The region at risk was assessed visually (at the boundary between occluded and non-occluded beds on the epicardial surface). Methylene blue was not used because of potential interference with immunoblots. 6 Diastolic arrest was produced with 1M KCl and the heart removed, rinsed in saline, weighed and quickly cut into five transverse sections parallel to the atrioventricular groove. Myocardial samples (~500 mg) were taken from the IZ (center of the LAD risk region) and the non-infarct zone (NIZ, center of the left circumflex bed), weighed and frozen in liquid N 2 for molecular assays. Tissue from sham hearts was also taken. The transverse sections were incubated in triphenyl tetrazolium chloride (TTC, 1% in 0.09 M sodium phosphate buffer pH 7.4; Fisher Scientific Co., Fairlawn, NJ) for 30 minutes at 37°C to delineate infarct tissue. The sections were then weighed and fixed in formalin. As described previously, 5, 6, 13, 14 tracings of LV rings, risk regions and infarct areas made on plastic overlays were planimetered (Hewlett Packard Vectra 486/33T computer; Summagraphics-Summasketch III) for infarct size. The anatomical boundaries of the risk area, between vessels at the margins of the occluded and non-occluded bed on the epicardial surface, were marked and the boundary line followed through the transmural thickness (from epicardium to endocardium) on the LV transverse sections, as described before. 6
Off-line analysis of echocardiograms As described previously, 5, 6, 13, 14 coded echocardiograms were analysed double-blind by playback of video tapes or optical disks for LV systolic functional parameters (total endocardial surface area of LV asynergy, defined as akinesia or dyskinesia or both); end-diastolic and end-systolic volumes; and global ejection fraction and remodelling parame-ters (expansion index 13, 14 or ratio of the lengths of asynergy-and non-asynergy-containing segments); thinning ratio or ratio of average thicknesses of the asynergic and non-asynergic zones. Endocardial and epicardial outlines (interobserver error <5%) were made using an electronic cursor and digitalised (Hewlett Packard Vectra computer).
Biochemical analyses
As described previously, 5,6 AT 1 -receptor, AT 2 -receptor and PKC ε proteins were assessed by Western immunoblots. Briefly, aliquots of LV tissue (10 mg) were homogenised (2% SDS [sodium dodecyl sulphate], 100 mmol/L dithiothreitol, 60 mmol/L Tris, pH 6.8) at 4°C and boiled at 100°C. The homogenate was subjected to electrophoresis on a 9% polyacrylamide gel (PAGE) in SDS followed by electrotransfer to nitrocellulose (Bio-Rad) at 4°C. The nitrocellulose membranes were blocked with phosphate-buffered saline (PBS), supplemented with 5% wt/vol skimmed milk powder, and 0.05% vol/vol of Tween 20. To assess AT 1receptor protein, the membranes were incubated with affinity-purified rabbit anti-human AT 1 -receptor antibody (Santa Cruz, CA) at 1:2000 dilution, for 2 hours at room temperature.The membranes were washed three times with PBS-Tween 20 (0.05%,TPBS), incubated with goat anti-rabbit IgG antibody (1:4000 dilution) conjugated to peroxidase and visualised using chemiluminescence detection (ECL Western blot kit,Amersham). Gels with 15 lanes were used. Protein assays were performed and equal amounts were loaded per lane. Band intensities were quantified by scanning densitometry using standard image analysis software (Sigma Gel, SPSS Inc., Chicago). To assess AT 2receptor protein, the same procedure was used as for AT 1 -receptor, except that incubation with goat anti-human AT 2 -receptor antibody (Santa Cruz, CA) at 1:500 dilution was followed by incubation with donkey anti-goat IgG (BioCan Scientific, Mississauga). To assess PKC ε proteins, cytosolic and membrane fractions were first separated by centrifugation (15,000 g) and steps described by Ping et al. 11 The same procedure as for AT 1 -receptor was then used, except that incubation with goat antihuman nPKC ε antibody (Santa Cruz, CA) at 1:100 dilution was followed by incubation with donkey anti-goat IgG (1:4000 dilution). Consistency in gel transfer efficiency was confirmed by reversible Ponceau staining and gel retention by Coomassie blue staining.Western immunoblots were performed in triplicate and results were expressed in arbitrary units of relative intensity (with the sham NIZ as 100%) and averaged. Tissue cGMP content was assessed by enzyme immunoassay (Amersham, UK) and expressed as fmol/mg wet weight. 6
Statistics
Data were analysed in blinded fashion, using analysis of variance (ANOVA) for the significance of difference within and between groups, and repeated measures ANOVA for comparing serial data within groups. Data are presented as mean±SEM. Statistical significance was set at p<0.05. 
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Results
Effects on in vivo haemodynamics
Baseline haemodynamics were similar between groups, mean values for the seven groups being: heart rate 146±3 bpm, left atrial pressure 6±0.2 mmHg, mean arterial pressure 125±3 mmHg. AT 1receptor blockade with CN produced significant inhibition of the Ang II pressor response before occlusion (80±11 vs. -14±22%, p<0.005). Haemodynamic parameters did not change in sham animals. After IR, mean left atrial pressure (an index of LV filling pressure) increased in control, AT 2receptor blockade and PKC, NO synthase and BK inhibition groups, but did not change in the CN group (Table 1) .
Effect on in vivo function and topography
The parameters did not change in sham animals (data not shown). Compared with control with IR, CN decreased LV end-diastolic volume, decreased relative IZ expansion and improved global ejection fraction, and these beneficial effects were abrogated by AT 2 -receptor blockade and inhibition of PKC, NO synthase or BK ( Figure 1 ). CN also decreased LV end-systolic volume compared with IR controls (-2±8 vs. 36±9%) and this effect was abolished by the respective inhibitors. At baseline, wall thickness (IZ, 9±1 mm; NIZ, 9±1 mm), thinning ratio (1±0), and LV asynergy (0±0%) were similar between groups. Compared with control with IR, CN decreased LV asynergy and IZ thinning, while PKC or BK inhibitor groups increased asynergy and IZ thinning ( Table 1) . Baseline diastolic functional parameters were similar between the groups, mean values being: E, 72±1 cm/s; A, 53±1 cm/s; E/A ratio, 1.3±0.1; DT, 141±1 ms. After IR in controls, peak E velocity decreased, peak A velocity increased, E/A ratio decreased, and DT increased. Importantly, CN increased the E/A ratio and decreased DT compared with IR controls (indicating improved diastolic relaxation) and these beneficial effects were attenuated by AT 2receptor blockade and inhibition of PKC, NO synthase or BK (Table 2) .
Effect on infarct size
No infarction was detected in sham hearts. Compared with the IR control group (Figure 2) , CN significantly reduced infarct size expressed as percent of risk region (25±2 vs. 52±3%, p<0.001) and as percent LV (p<0.05). This benefit was abrogated by AT 2 -receptor blockade and inhibition of PKC, NO synthase or BK. Importantly, infarct size increased significantly, both as percent risk region and LV, with PKC inhibition (76±3 vs. 52±3% risk, p<0.001) and BK inhibition (78±1 vs. 52±3% risk, p<0.001), compared with the control group.
Effect on AT 1 -receptor and AT 2 -receptor proteins (Figure 3)
There was no difference in AT 1 -receptor protein levels for the IZ and NIZ of hearts in sham, control, CN, AT 2 -receptor blockade and PKC, NO synthase or BK inhibition groups ( Figure 3A) . In contrast, there was a 3-fold regional increase in AT 2 -receptor protein level in the IZ of CN hearts compared with the NIZ and either zone of control and sham 
Changes are from baseline. hearts, and this regional increase was abrogated by AT 2 -receptor blockade and PKC, NO synthase or BK inhibition ( Figure 3B ).
Effect on total and membrane PKC ε proteins (Figure 4)
There was a 4.7-fold regional increase in total PKC ε protein in the IZ of the CN hearts compared with the NIZ and either zone of control and sham hearts, and this effect was abolished by AT 2 -receptor blockade and PKC, NO synthase or BK inhibition ( Figure 4 ). Similar changes were found for membrane PKC ε (not shown), with a 2-fold increase in the IZ of CN hearts compared with other groups (p<0.001).
Effect on cGMP (Figure 5)
There was an increase in LV cGMP content in the IZ and NIZ of hearts with MI compared with sham (p<0.05) and a further 1.4-fold increase in the IZ of CN hearts compared with the MI hearts ( Figure  5 ). This further increase in cGMP with CN (compared with MI hearts) was attenuated by AT 2receptor blockade and inhibition of NO synthase and BK but not by inhibition of PKC, which still showed a 1.3-fold increase (p<0.05) in the IZ compared with MI hearts.
Discussion
The results of the present study indicate that, in a well characterised in vivo adult dog model of acute IR injury, 5, 6, 16 cardioprotection and the concomitant regional increases in AT 2 -receptor and PKC ε proteins in the IZ associated with AT 1 -receptor blockade are abrogated by AT 2 -receptor blockade and inhibition of PKC, NO synthase or BK. In addition, AT 2 -receptor blockade and inhibition of NO synthase or BK attenuate the increase in LV cGMP content induced by AT 1 -receptor blockade but this effect is not seen with PKC inhibition. These findings imply that AT 2 -receptor activation and signalling via BK, PKC ε and cGMP contribute to the cardioprotective effect.
Mechanisms
In this study, pharmacological evidence of AT 1 -PAPER Table 2 Percent changes in diastolic function (transmitral doppler).
Group E velocity A velocity E/A ratio DT
Changes are from baseline. A = late filling; CN = candesartan; DT = deceleration time; E = early filling; other abbreviations as in Table 1 . * p<0.01, compared to value in control; †p<0.001, control vs. sham. Evidence of cardioprotection included the decrease in LV preload, asynergy, diastolic dimension, IZ expansion and infarct size, and improvements in systolic and diastolic function. These beneficial effects are consistent with a decrease in myocardial necrosis, stunning and vasodilation. The decrease in LV diastolic load, size and wall stress is consistent with venodilation. It is not clear whether perfusion improved, since we did not measure regional myocardial blood flow. However, it is known that, in dog hearts, acute coronary occlusion can result in fairly low-flow ischaemia 17 and necrosis develops in moderately ischaemic myocardium after IR. 16 In addition, AT 1 -receptor blockade attenuates myocardial stunning without improving ischaemic flow in the very low-flow dog model of IR. 18 Similarly, in the minipig model of very low-flow IR, AT 1 -receptor blockade decreases infarct size without increasing ischaemic flow. 4 Moreover, in both the minipig model 4 and our dog model in this study, the reduction in infarct size was abolished by AT 2 -receptor and BK antagonists, implicating AT 2 -receptors and BK in the cardioprotective effects. In this study, the increase in AT 2 -receptor protein was also associated with an increase in LV cGMP content (an index of NO formation) and this effect was abolished by inhibitors of both endothelial NO synthase and BK. It has already been shown that AT 2 -receptors stimulate the NO-cGMP pathway via BK secretion. 19, 20 In canine coronary arteries, AT 2 -receptor activation increases BK and NO release. 21 In stroke-prone spontaneously hypertensive rats,AT 2 -receptor stimulation by Ang II increases aortic cGMP by increasing BK and NO. 20 Taken together, these findings support the notion that AT 1receptor blockade during IR leads to AT 2 -receptor activation, which stimulates BK and NO production, thereby increasing cGMP and contributing to cardioprotection ( Figure 6 ).
The paradigm that inhibition of certain cardiac actions of Ang II through the AT 1 -receptor (such as vasoconstriction, inotropism and chronotropism) confers cardioprotection during IR [1] [2] [3] [4] [5] [6] [8] [9] [10] 18, 22 is now expanding to include AT 2 -receptor involvement. Molecular cloning and pharmacological studies indicate that AT 2 -receptors are not only functional and are activated during AT 1 -receptor blockade, but are also involved in cross-talk with AT 1 -receptors in adult hearts. 22 AT 2 -receptors are also antiproliferative and mediate vascular apoptosis. 23 AT 2 -receptor-knockout mice show increased vascular reactivity to Ang II and AT 1 -receptor expression, suggesting that AT 2 -receptors counteract AT 1receptor-mediated vasoconstriction via AT 1 -receptor downregulation. 24 AT 2 -receptor gene deletion studies in mice suggest that AT 2 -receptors protect against pressor and anti-natriuretic actions of Ang II via BK and NO. 19 Data from transgenic mice with overexpression of cardiac AT 2 -receptors, 25 suggest that AT 1 -receptor-mediated pressor and chronotropic responses are attenuated without affecting contractility. Since Ang II increases after IR, 26 when the AT 1 -receptors are blocked, Ang II would be expected to upregulate AT 2 -receptors which would stimulate NO production and downregulate AT 1 -receptor, 27 thereby limiting vasoconstriction. It is possible that the beneficial effects of AT 1receptor blockade and a mechanism involving effects of AT 2 -receptor-BK-NO-cGMP on IR injury, may more than offset other potentially harmful effects, such as Ang II stimulation of superoxide radicals (·O 2 -). 12, 28 These radicals can rapidly degrade free NO 26 and react with NO to form peroxynitrite (ONOO -) which, in turn, decomposes to generate hydroxyl radical (·OH) that could enhance IR injury. 12 Release of prostacyclin (PGI 2 ) has also been implicated in the cardioprotective effect of AT 1 -receptor blockade, since cyclooxygenase (COX) inhibition abolishes the infarct-limiting effect. 4 Our data supports the view that AT 2 -receptor signal transduction pathways include NO production and increase in cGMP. 22 Our finding of no change in AT 1 -receptor protein in the IZ is consistent with AT 1 -receptor downregulation secondary to AT 2 -receptor activation and increased NO. The concomitant increases in AT 2 -receptor and PKC ε proteins, plus the increase in cGMP induced by AT 1receptor blockade, and the abolition of these effects by AT 2 -receptor blockade, imply that they are associated with IR and AT 1 -receptor blockade. Although NO-induced selective PKC ε activation is a critical signalling step in cardioprotection associated with late ischaemic preconditioning in rabbits, 11 and inhibition of PKC in our study abrogated the regional increases in AT 2 -receptor and PKC ε proteins after AT 1 -receptor blockade, PKC inhibition, surprisingly, did not attenuate the increase in LV cGMP. This suggests that factors other than PKC ε also mediate the increase in cGMP during AT 1receptor blockade. However, both endothelial NO synthase and BK inhibition attenuated the increase in cGMP induced by AT 1 -receptor blockade, as well as the regional increases in AT 2 -receptor and PKC ε proteins. Since BK, acting through the B 2 receptor, initiates events leading to activation of PKC, 29 the increase in PKC ε appears to be linked with increased BK and AT 2 -receptor activation.
Implications
Our findings suggest that enhanced AT 2 -receptor expression might have important implications for pharmacotherapy with AT 1 -receptor antagonists. They are especially pertinent for hypertensive patients who succumb to acute coronary syndromes during AT 1 -receptor blocker therapy.
Limitations
Our findings in this study raise several questions that require further investigation. For example: 1) we did not detect a change in AT 1 -receptor,AT 2receptor or PKC ε protein, although we previously showed that IR alone was associated with an increase in AT 2 -receptor mRNA and protein and AT 1 -receptor mRNA but not AT 1 -receptor protein in a large number of canine hearts. 6 2) We did not detect an effect of BK, NO, or PKC inhibition on AT 2 -receptor protein. 3) We did not determine the protein changes with more than 2 hours of reperfusion or with more prolonged pretreatment with the AT 1 -receptor blocker. 4) We did not study the effect of AT 2 -receptor, BK, PKC or NO blockade alone on infarct size and AT 1 -receptor and AT 2receptor expression.
Conclusions
The present study shows that cardioprotective effects of AT 1 -receptor blockade on LV remodelling, systolic and diastolic dysfunction and infarct size during acute IR, and the associated increases in AT 2receptor and PKC ε proteins and cGMP, are abolished by AT 2 -receptor blockade or inhibition of NO synthase and BK,and all except the increase in cGMP by PKC inhibition. The overall results suggest that the cardioprotection associated with AT 1 -receptor blockade during IR injury involves AT 2 -receptor activation and downstream signalling via BK, PKC ε , NO and cGMP. Whether this is true in humans needs further investigation.
